To inform a phase I clinical trial containing predominantly patients with CRC (a total number of 19 CRC patients representing 47% of all patients recruited to this phase I trial [6]) for potential combination treatments with AZD0424, we applied RPPA to profile the response of four CRC cell lines with mutations in the KRAS gene, a common mutation in CRC, to treatment with the MEK inhibitor trametinib and AZD6244. This evidence concerns the gene MAP2K7 and colorectal carcinoma.